The firm's microfluidic diagnostic system uses phenotypic bacteria growth analysis to enable rapid antibiotic testing and treatment of sepsis patients.
To combat the challenge of counterfeit diagnostic tests, IBM scientists have developed a method to embed security codes to authenticate diagnostic tests.
The researchers have prospectively validated a disposable cartridge-based microfluidic assay by obtaining results using fine-needle aspirates in 40 patients.
The startup's technology uses a droplet microfluidics approach for cell isolation and phenotypic detection, and is being targeted for use by hospitals.
Inspired by the electronic breadboards used to prototype electronic devices, the system is meant to enable flexible and inexpensive design of clinical tests.
According to project organizers, feasibility testing in the first phase of the project was successful and clinical trials are planned for later this year.
